3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
3
Withdrawn
2
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
25
Stomach Neoplasms
11
Pancreatic Neoplasms
11
Colonic Neoplasms
9
Rectal Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Esophageal Neoplasms
6
Adenocarcinoma Of Esophagus
6
Neoplasms
5
Cholangiocarcinoma
5
Burkitt Lymphoma
5
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Urinary Bladder Neoplasms
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Lung Neoplasms
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Urachal cancer
1
Unresectable Colorectal Cancer
1
Triple Negative Breast Neoplasms
1
Interventions
Carboplatin
25
Paclitaxel
24
pembrolizumab
22
Cyclophosphamide
14
Gemcitabine
10
Capecitabine
10
Doxorubicin
9
Specimen Handling
8
Nivolumab
8
Taxes
7
Magnetic Resonance Spectroscopy
7
sacituzumab govitecan
6
olaparib
6
Cisplatin
6
eribulin
5
durvalumab
5
atezolizumab
5
Radiotherapy
5
Albumin-Bound Paclitaxel
5
130-nm albumin-bound paclitaxel
5
capivasertib
4
Epirubicin
4
Docetaxel
4
Biopsy
4
niraparib
3
Vinorelbine
3
Radiation
3
Fulvestrant
3
Blood Specimen Collection
3
trastuzumab deruxtecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Triple Negative Breast Neoplasms
×
Leucovorin
×
Clear all
NCT05891171
2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled